Ramón Colomer Bosch-rekin lankidetzan egindako argitalpenak (8)

2020

  1. Membrane disruption, but not metabolic rewiring, is the key mechanism of anticancer-action of FASN-inhibitors: a multi-omics analysis in ovarian cancer

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. Essentiality of fatty acid synthase in the 2D to anchorage-independent growth transition in transforming cells

    Nature Communications, Vol. 10, Núm. 1

2017

  1. Multi-level suppression of receptor-PI3K-mTORC1 by fatty acid synthase inhibitors is crucial for their efficacy against ovarian cancer cells

    Oncotarget, Vol. 8, Núm. 7, pp. 11600-11613

2015

  1. Fatty acid synthase is a metabolic marker of cell proliferation rather than malignancy in ovarian cancer and its precursor cells

    International Journal of Cancer, Vol. 136, Núm. 9, pp. 2078-2090

2012

  1. New synthetic inhibitors of fatty acid synthase with anticancer activity

    Journal of Medicinal Chemistry, Vol. 55, Núm. 11, pp. 5013-5023

2011

  1. A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines

    Breast Cancer Research, Vol. 13, Núm. 6

2010

  1. Novel anti-fatty acid synthase compounds with anti-cancer activity in HER2+ breast cancer

    Annals of the New York Academy of Sciences, Vol. 1210, Núm. 1, pp. 86-92

2009

  1. Novel inhibitors of fatty acid synthase with anticancer activity

    Clinical Cancer Research, Vol. 15, Núm. 24, pp. 7608-7615